Adeel Ahmed-Daudpota
Chief Executive Officer chez IMMUNE PHARMACEUTICALS, INC.
Profil
Adeel Ahmed-Daudpota currently works at Immune Pharmaceuticals, Inc., as President & Chief Executive Officer from 2021.
Postes actifs de Adeel Ahmed-Daudpota
Sociétés | Poste | Début |
---|---|---|
IMMUNE PHARMACEUTICALS, INC. | Chief Executive Officer | 12/04/2021 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |